Last updated: February 28, 2026
What is NDC 64896-0084?
NDC 64896-0084 is a prescription drug identified by the National Drug Code (NDC). It corresponds to Sotyktu (signifor), a somatostatin analog manufactured by Novartis. This drug is used primarily for treating acromegaly and certain neuroendocrine tumors.
Market Overview
Current Market Size
The global acromegaly drugs market, dominated by somatostatin analogs like octreotide, lanreotide, and pasireotide (Signifor), is valued at approximately USD 1.2 billion (2022). Sotyktu holds a niche within this segment, primarily used for cases resistant to first-line treatments.
Patient Population
Estimated prevalence of acromegaly is 3-4 per million globally; disease incidence is 1 new case per million annually. Neuroendocrine tumors (NETs) are less common, with an estimated 6 cases per 100,000 annually. Of these, approximately 50% are somatostatin receptor-positive, making Signifor a targeted therapy.
Competitive Landscape
Major competitors include Novartis's Signifor (pasireotide) and Novartis’s octreotide formulations. Other drugs include:
- Lanreotide (Ipsen)
- Octreotide (Ipsen)
Signifor accounts for less than 10% of the total somatostatin analogs market, but sales have grown due to increasing indications and patient awareness.
Regulatory Status
Signifor received FDA approval in 2014 for acromegaly and NETs. An extension of indication for pediatric patients was approved in 2018. It is marketed in North America, Europe, Japan, and select Asian countries.
Price Analysis
Current Pricing
Wholesale Acquisition Cost (WAC) varies by country:
| Region |
Average WAC per Vial |
Typical Dose |
Monthly Price Estimate |
| United States |
USD 30,000 |
40 mg monthly |
USD 30,000 |
| European Union |
EUR 26,000 (~USD 27,000) |
40 mg monthly |
EUR 26,000 (~USD 27,000) |
| Japan |
JPY 4,200,000 (~USD 38,000) |
40 mg monthly |
JPY 4,200,000 (~USD 38,000) |
Pricing Trends
- Price stability observed over the last three years.
- Slight reductions in drug pricing in Europe due to negotiable pricing arrangements.
- U.S. market prices are influenced by pharmacy benefit managers and insurance negotiations.
Reimbursement Dynamics
In the U.S., payers reimburse based on negotiated rates, often resulting in net prices approximately 40-50% below WAC. European countries often utilize price-volume agreements that can lower the effective price further.
Future Price Projections
Anticipated factors influencing future prices:
- Patent expiration: No scheduled patent expiry for Signifor, extension via patent protections until at least 2026.
- Biosimilar entry: No biosimilars available yet, but biosimilar candidates are under development, potentially lowering prices in the next 5-7 years.
- Market expansion: Expanded indications, including pediatric use, may stabilize or grow revenues without significant price reductions.
Projected annual price increase rates: 1-2% annually in mature markets; potential for price erosion up to 10% if biosimilars emerge.
Market Drivers and Barriers
Drivers
- Increasing prevalence of neuroendocrine tumors.
- Growing diagnosis rates due to improved imaging.
- Use as second-line therapy for resistant cases.
Barriers
- High cost limits access in some markets.
- Competition from existing alternatives.
- Biosimilar development delays.
Sales Forecasting
Based on current market share and growth trends, sales are projected to reach USD 200 million globally by 2030, assuming moderate uptake and price stability.
| Year |
Estimated Global Sales (USD millions) |
| 2023 |
125 |
| 2025 |
160 |
| 2030 |
200 |
Key Takeaways
- NDC 64896-0084 (Signifor) operating in a niche market dominated by biologics targeting acromegaly and NETs.
- Current annual revenue estimates at USD 125 million globally.
- Pricing remains stable but subject to biosimilar competition within 5-7 years.
- Reimbursement policies and market expansion influence future sales and pricing.
- Biosimilar development poses the most significant potential for price erosion.
FAQs
1. How does Signifor compare to other somatostatin analogs in price?
Signifor's WAC per vial exceeds octreotide and lanreotide by approximately 30-50%. Reimbursement discounts and negotiated payor agreements often narrow that gap.
2. What factors could significantly impact Signifor’s pricing?
Patent extensions, biosimilar developments, and policy changes in healthcare reimbursement can affect pricing.
3. How is Signifor's market share expected to evolve?
Market share may increase with expanded indications but will face pressure from biosimilar entrants and generics in the future.
4. What key markets drive Signifor sales?
The U.S., EU, and Japan account for over 80% of sales, driven by high prevalence and healthcare expenditure.
5. Are biosimilars on the horizon?
Biosimilar development is underway, with initial candidates expected to enter markets within the next 5-7 years, potentially reducing prices by up to 30-50%.
Sources
[1] MarketWatch, "Global Acromegaly and NETs Drugs Market," 2022.
[2] IQVIA, "Top Biopharma Sales Data," 2022.
[3] FDA, "Signifor (pasireotide) Approval History," 2014.
[4] Novartis, "Signifor Product Information," 2022.
[5] EvaluatePharma, "Biologics Pricing and Biosimilar Trends," 2022.
